A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Status:
Active, not recruiting
Trial end date:
2021-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how well monoclonal antibodies work, either alone or
in combination, against the virus that causes COVID-19. Study drug(s) will be given to
participants with early symptoms of COVID-19. Samples will be taken from the back of the nose
to determine how much virus is in the body at various times during the study. Participation
could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the
remainder of assessments performed in the home, local clinic, or by phone.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
AbCellera Biologics Inc. GlaxoSmithKline Shanghai Junshi Bioscience Co., Ltd. Vir Biotechnology, Inc.